BRPI0923164A2 - formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica. - Google Patents

formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica.

Info

Publication number: BRPI0923164A2
Authority: BR; Brazil
Prior art keywords: treatment; short; actinic keratosis; imiquimod formulations; dosage
Prior art date: 2008-12-19

Application number

BRPI0923164A

Other languages

English (en)

Inventor

James H Kulp

James H Lee

Jason J Wu

Kodumudi S Balaji

Mchael T Nordsiek

Robert Babilon

Sharon F Levy

Tze-Chiang Meng

Valyn S Bahm

Original Assignee

Graceway Pharmaceuticals Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-19

Filing date

2009-12-11

Publication date

2016-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923164(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-11 Application filed by Graceway Pharmaceuticals Llc filed Critical Graceway Pharmaceuticals Llc

2016-01-26 Publication of BRPI0923164A2 publication Critical patent/BRPI0923164A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)

BRPI0923164A 2008-12-19 2009-12-11 formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica. BRPI0923164A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US13953608P	2008-12-19	2008-12-19
US14473109P	2009-01-14	2009-01-14
US20514509P	2009-01-15	2009-01-15
PCT/US2009/067759 WO2010080345A1 (en)	2008-12-19	2009-12-11	Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis

Publications (1)

Publication Number	Publication Date
BRPI0923164A2 true BRPI0923164A2 (pt)	2016-01-26

Family

ID=42316709

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0923164A BRPI0923164A2 (pt)	2008-12-19	2009-12-11	formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica.

Country Status (28)

Country	Link
US (13)	US20110021555A1 (pt)
EP (1)	EP2378876B1 (pt)
AR (1)	AR074802A1 (pt)
AU (1)	AU2009335943A1 (pt)
BR (1)	BRPI0923164A2 (pt)
CL (1)	CL2009002183A1 (pt)
CO (1)	CO6400171A2 (pt)
CR (1)	CR20110338A (pt)
CY (1)	CY1121485T1 (pt)
DK (1)	DK2378876T3 (pt)
DO (1)	DOP2011000195A (pt)
EA (1)	EA201100984A1 (pt)
ES (1)	ES2720149T3 (pt)
GE (1)	GEP20146198B (pt)
HR (1)	HRP20190306T1 (pt)
HU (1)	HUE041944T2 (pt)
IL (2)	IL213628A (pt)
LT (1)	LT2378876T (pt)
MX (2)	MX2011001555A (pt)
PA (1)	PA8855101A1 (pt)
PE (2)	PE20142367A1 (pt)
PL (1)	PL2378876T3 (pt)
PT (1)	PT2378876T (pt)
RS (1)	RS58566B1 (pt)
SI (1)	SI2378876T1 (pt)
SM (1)	SMT201900195T1 (pt)
TW (1)	TWI442923B (pt)
WO (1)	WO2010080345A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100160368A1 (en) *	2008-08-18	2010-06-24	Gregory Jefferson J	Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US20110030089A1 (en)	2008-08-29	2011-02-03	Los Alamos National Security, Llc	Transgenic plants with enhanced growth characteristics
US20110030104A1 (en)	2008-08-29	2011-02-03	Los Alamos National Security, Llc	Nucleic acids encoding plant glutamine phenylpyruvate transaminase (GPT) and uses thereof
MX2011001555A (es)	2008-12-19	2011-04-14	Graceway Pharmaceuticals Llc	Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica.
EP2453747B1 (en)	2009-07-13	2017-08-30	Medicis Pharmaceutical Corporation	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
EA201291442A1 (ru)	2010-06-25	2013-04-30	Медисиз Фармасьютикал Корпорейшн	Комбинированная терапия с криохирургией и имиквимодом с низкой дозировкой для лечения актинического кератоза
US9072876B2 (en)	2010-08-05	2015-07-07	Medicis Pharmaceutical Corporation	Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9492682B2 (en)	2011-09-14	2016-11-15	Medicis Pharmaceutical Corporation	Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
BR112014013227A2 (pt) *	2011-11-30	2017-06-13	Merz Pharma Gmbh & Co Kgaa	uso de álcoois peguilados no tratamento de queratose actínica
CA2871490C (en)	2012-04-27	2022-10-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
MX371496B (es)	2013-08-30	2020-01-31	Immunogen Inc	Anticuerpos y ensayos para la detección del receptor 1 de folato.
US9711014B2 (en)	2013-09-06	2017-07-18	Immersion Corporation	Systems and methods for generating haptic effects associated with transitions in audio signals
US9619980B2 (en)	2013-09-06	2017-04-11	Immersion Corporation	Systems and methods for generating haptic effects associated with audio signals
US9576445B2 (en)	2013-09-06	2017-02-21	Immersion Corp.	Systems and methods for generating haptic effects associated with an envelope in audio signals
NZ757964A (en) *	2013-10-08	2022-07-01	Immunogen Inc	Anti-folr1 immunoconjugate dosing regimens
BR112017004893A2 (pt) *	2014-09-10	2017-12-12	Univ Washington	composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
CN108601828B (zh)	2015-09-17	2023-04-28	伊缪诺金公司	包含抗folr1免疫缀合物的治疗组合
CN110891575A (zh) *	2017-03-10	2020-03-17	雅培克公司	治疗和/或预防光化性角化病的方法
WO2020180424A1 (en)	2019-03-04	2020-09-10	Iocurrents, Inc.	Data compression and communication using machine learning

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE24906E (en)	1955-11-18	1960-12-13		Pressure-sensitive adhesive sheet material
US4722941A (en) *	1978-06-07	1988-02-02	Kali-Chemie Pharma Gmbh	Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) *	1981-08-14	1983-10-25	Minnesota Mining And Manufacturing Company	Topical medicament preparations
IL73534A (en) *	1983-11-18	1990-12-23	Riker Laboratories Inc	1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4751087A (en) *	1985-04-19	1988-06-14	Riker Laboratories, Inc.	Transdermal nitroglycerin delivery system
US4746515A (en)	1987-02-26	1988-05-24	Alza Corporation	Skin permeation enhancer compositions using glycerol monolaurate
US5238944A (en)	1988-12-15	1993-08-24	Riker Laboratories, Inc.	Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SE9601528D0 (sv)	1996-04-23	1996-04-23	Pharmacia Ab	Transdermally administered dextromethorphan as antitissue agent
UA67760C2 (uk)	1997-12-11	2004-07-15	Міннесота Майнінг Енд Мануфакчурінг Компані	Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US20030007939A1 (en) *	1998-07-31	2003-01-09	Howard Murad	Pharmaceutical compositions and methods for managing dermatological conditions
US20020058674A1 (en) *	1999-01-08	2002-05-16	Hedenstrom John C.	Systems and methods for treating a mucosal surface
HU229441B1 (en)	1999-01-08	2013-12-30	3M Innovative Properties Co	Formulations and methods for treating mucosal associated conditions with an immune response modifier
US20030072814A1 (en) *	1999-12-16	2003-04-17	Maibach Howard I.	Topical pharmaceutical composition for the treatment of warts
US6894060B2 (en)	2000-03-30	2005-05-17	3M Innovative Properties Company	Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en)	2000-09-15	2002-05-09	3M Innovative Properties Company	Methods for delaying recurrence of herpes virus symptoms
JP2005519849A (ja)	2001-06-15	2005-07-07	スリーエムイノベイティブプロパティズカンパニー	歯周病の治療用免疫応答調節剤
NZ532769A (en) *	2001-11-29	2005-12-23	3M Innovative Properties Co	Pharmaceutical formulations comprising an immune response modifier
US9668972B2 (en)	2002-10-25	2017-06-06	Foamix Pharmaceuticals Ltd.	Nonsteroidal immunomodulating kit and composition and uses thereof
US7893083B2 (en) *	2003-01-06	2011-02-22	Eugene Mandrea	Method of treating genital herpes
US7699057B2 (en) *	2003-03-13	2010-04-20	3M Innovative Properties Company	Methods for treating skin lesions
ATE556711T1 (de) *	2003-03-13	2012-05-15	3M Innovative Properties Co	Verfahren zur verbesserung der hautqualität
US20040192585A1 (en)	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
US20090232755A1 (en) *	2003-07-28	2009-09-17	Leslie Baumann	Combination therapies for treating photodamaged skin
US7521459B2 (en) *	2003-07-28	2009-04-21	Metabeauty Inc.	Method for treating damaged skin
WO2005020995A1 (en)	2003-09-02	2005-03-10	3M Innovative Properties Company	Methods related to the treatment of mucosal associated conditions
AU2004312547A1 (en)	2003-12-31	2005-07-21	Taigen Biotechnology	Protease inhibitors
WO2005077411A2 (en) *	2004-02-10	2005-08-25	Innate Pharma	Composition and method for the treatment of carcinoma
US20080125485A1 (en) *	2004-02-17	2008-05-29	Action Medicines	Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
US20070166384A1 (en) *	2004-04-09	2007-07-19	Zarraga Isidro Angelo E	Methods , composition and preparations for delivery of immune response modifiers
US20070196452A1 (en)	2004-06-07	2007-08-23	Jie Zhang	Flux-enabling compositions and methods for dermal delivery of drugs
CN1286529C (zh)	2004-06-11	2006-11-29	华中科技大学	具有皮肤靶向性的药物组合物及其制备方法和用途
US20060062755A1 (en) *	2004-09-21	2006-03-23	Woodward John R	Method of cancer screening; method of cancer treatment; and method of diabetes treatment
DE102004049223A1 (de) *	2004-10-08	2006-04-20	Johannes-Gutenberg-Universität Mainz	Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US20060105028A1 (en) *	2004-11-12	2006-05-18	Jie Zhang	Systems and methods for treating warts
US8080560B2 (en) *	2004-12-17	2011-12-20	3M Innovative Properties Company	Immune response modifier formulations containing oleic acid and methods
AU2006210392A1 (en)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune response modifiers
WO2007025999A1 (en) *	2005-08-31	2007-03-08	Serentis Limited	Use of an aureolysin inhibitor for the treatment of inflammatory skin conditions characterised by colonisation with staphylococcus aureus
WO2007032009A2 (en) *	2005-09-15	2007-03-22	Biomas Ltd.	Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis
US8889154B2 (en)	2005-09-15	2014-11-18	Medicis Pharmaceutical Corporation	Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US20070081962A1 (en)	2005-10-06	2007-04-12	Amit Munshi	Novel delivery of immune response modifiers for removal of chronic tattoos
GB0524962D0 (en) *	2005-12-07	2006-01-18	Pharmakodex Ltd	Topical pharmaceutical compositions
US20070264317A1 (en)	2006-05-15	2007-11-15	Perrigo Israel Pharmaceuticals Ltd.	Imiquimod cream formulation
ES2393761T3 (es) *	2006-07-14	2012-12-27	Stiefel Research Australia Pty Ltd	Espuma farmacéutica de ácido graso
WO2008010963A2 (en)	2006-07-18	2008-01-24	3M Innovative Properties Company	Immune response modifier formulations
WO2008016475A2 (en)	2006-07-31	2008-02-07	3M Innovative Properties Company	Immune response modifier compositions and methods
DK2076260T3 (da) *	2006-09-15	2011-06-27	Celgene Corp	N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
HUE035389T2 (en) *	2006-09-26	2018-05-02	Celgene Corp	5-substituted quinazolinone derivatives as anticancer agents
EP2115140B8 (en) *	2007-01-31	2017-01-25	Chongxi Yu	Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
US20090018155A1 (en)	2007-02-08	2009-01-15	Gregory Jefferson J	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US20080280943A1 (en) *	2007-03-23	2008-11-13	Slade Herbert B	Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008118765A1 (en)	2007-03-23	2008-10-02	Graceway Pharmaceuticals, Llc	Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008140713A1 (en)	2007-05-08	2008-11-20	The Brigham And Women's Hospital, Inc	Methods and products for treating proliferative disorders
US8636982B2 (en) *	2007-08-07	2014-01-28	Foamix Ltd.	Wax foamable vehicle and pharmaceutical compositions thereof
GB0715428D0 (en)	2007-08-08	2007-09-19	Imp Innovations Ltd	Compositions and uses thereof
US20090130029A1 (en) *	2007-11-21	2009-05-21	Foamix Ltd.	Glycerol ethers vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) *	2007-11-30	2009-06-04	Foamix Ltd.	Foam containing benzoyl peroxide
CA2708203A1 (en)	2008-01-15	2009-07-23	Dow Pharmaceutical Sciences, Inc.	Imiquimod formulation
KR101483715B1 (ko)	2008-01-31	2015-01-19	큐어백 게엠바하	면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
US20090246156A1 (en) *	2008-03-31	2009-10-01	Audrey Kunin	Anti-acne sunscreen composition
CN102046180A (zh) *	2008-04-03	2011-05-04	同源3公司	用于免疫治疗的组合物和方法
JP2011518885A (ja)	2008-04-28	2011-06-30	ノバルティスアーゲー	医薬組成物における使用のためのナノ粒子
EP2303280A2 (en)	2008-05-30	2011-04-06	Novelix Pharmaceuticals, Inc.	Compositions and methods for treatment of inflammation and hyperkeratotic lesions
BRPI0914630A2 (pt)	2008-06-26	2019-09-24	Anterios Inc	liberação dérmica
US20100160368A1 (en)	2008-08-18	2010-06-24	Gregory Jefferson J	Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US8343498B2 (en) *	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
EP2340043A4 (en)	2008-10-31	2012-09-19	Moberg Derma Ab	TOPICAL COMPOSITION COMPRISING A COMBINATION OF AT LEAST TWO PENETRATION AGENTS
MX2011001555A (es)	2008-12-19	2011-04-14	Graceway Pharmaceuticals Llc	Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica.
WO2010088924A1 (en)	2009-02-06	2010-08-12	Telormedix Sa	Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2453747B1 (en)	2009-07-13	2017-08-30	Medicis Pharmaceutical Corporation	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US8476225B2 (en)	2009-12-04	2013-07-02	Gilead Sciences, Inc.	Antiviral compounds
US9072876B2 (en) *	2010-08-05	2015-07-07	Medicis Pharmaceutical Corporation	Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9492682B2 (en) *	2011-09-14	2016-11-15	Medicis Pharmaceutical Corporation	Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis

2009
- 2009-12-11 MX MX2011001555A patent/MX2011001555A/es active IP Right Grant
- 2009-12-11 SI SI200931933T patent/SI2378876T1/sl unknown
- 2009-12-11 WO PCT/US2009/067759 patent/WO2010080345A1/en not_active Ceased
- 2009-12-11 EA EA201100984A patent/EA201100984A1/ru unknown
- 2009-12-11 RS RS20190210A patent/RS58566B1/sr unknown
- 2009-12-11 PL PL09837849T patent/PL2378876T3/pl unknown
- 2009-12-11 AU AU2009335943A patent/AU2009335943A1/en not_active Abandoned
- 2009-12-11 HU HUE09837849A patent/HUE041944T2/hu unknown
- 2009-12-11 SM SM20190195T patent/SMT201900195T1/it unknown
- 2009-12-11 PT PT09837849T patent/PT2378876T/pt unknown
- 2009-12-11 HR HRP20190306TT patent/HRP20190306T1/hr unknown
- 2009-12-11 BR BRPI0923164A patent/BRPI0923164A2/pt not_active Application Discontinuation
- 2009-12-11 US US12/636,613 patent/US20110021555A1/en not_active Abandoned
- 2009-12-11 ES ES09837849T patent/ES2720149T3/es active Active
- 2009-12-11 LT LTEP09837849.0T patent/LT2378876T/lt unknown
- 2009-12-11 DK DK09837849.0T patent/DK2378876T3/en active
- 2009-12-11 GE GEAP200912310A patent/GEP20146198B/en unknown
- 2009-12-11 MX MX2015008994A patent/MX346455B/es unknown
- 2009-12-11 EP EP09837849.0A patent/EP2378876B1/en active Active
- 2009-12-17 TW TW098143460A patent/TWI442923B/zh active
- 2009-12-17 CL CL2009002183A patent/CL2009002183A1/es unknown
- 2009-12-18 PE PE2014000347A patent/PE20142367A1/es not_active Application Discontinuation
- 2009-12-18 PE PE2009001323A patent/PE20100469A1/es not_active Application Discontinuation
- 2009-12-18 AR ARP090104978A patent/AR074802A1/es unknown
- 2009-12-18 PA PA20098855101A patent/PA8855101A1/es unknown
2011
- 2011-06-16 IL IL213628A patent/IL213628A/en active IP Right Grant
- 2011-06-17 DO DO2011000195A patent/DOP2011000195A/es unknown
- 2011-06-17 CR CR20110338A patent/CR20110338A/es unknown
- 2011-07-08 US US13/179,315 patent/US8222270B2/en active Active
- 2011-07-08 US US13/179,336 patent/US20110263633A1/en not_active Abandoned
- 2011-07-08 US US13/179,363 patent/US20110257217A1/en not_active Abandoned
- 2011-07-08 US US13/179,402 patent/US20110263634A1/en not_active Abandoned
- 2011-07-12 US US13/181,507 patent/US20110257219A1/en not_active Abandoned
- 2011-07-12 US US13/181,499 patent/US8236816B2/en active Active
- 2011-07-13 US US13/182,433 patent/US8299109B2/en active Active
- 2011-07-13 CO CO11087690A patent/CO6400171A2/es not_active Application Discontinuation
- 2011-07-17 US US13/184,556 patent/US20110263636A1/en not_active Abandoned
- 2011-07-18 US US13/184,579 patent/US20110263637A1/en not_active Abandoned
2012
- 2012-08-06 US US13/568,003 patent/US9370509B2/en active Active
2016
- 2016-06-20 US US15/187,751 patent/US10238644B2/en active Active
2017
- 2017-10-22 IL IL255163A patent/IL255163B/en active IP Right Grant
2019
- 2019-02-05 US US16/268,230 patent/US11318130B2/en active Active
- 2019-02-14 CY CY20191100200T patent/CY1121485T1/el unknown

Also Published As

Publication number	Publication date
DOP2011000195A (es)	2011-12-15
WO2010080345A1 (en)	2010-07-15
IL213628A (en)	2017-11-30
PE20142367A1 (es)	2015-01-10
PL2378876T3 (pl)	2019-06-28
CY1121485T1 (el)	2020-05-29
HUE041944T2 (hu)	2019-06-28
IL213628A0 (en)	2011-07-31
IL255163A0 (en)	2017-12-31
US20110263637A1 (en)	2011-10-27
US20110263633A1 (en)	2011-10-27
HRP20190306T1 (hr)	2019-05-03
DK2378876T3 (en)	2019-03-11
US20110257219A1 (en)	2011-10-20
EP2378876B1 (en)	2018-11-14
AR074802A1 (es)	2011-02-16
US10238644B2 (en)	2019-03-26
US20130210855A1 (en)	2013-08-15
GEP20146198B (en)	2014-11-25
US8299109B2 (en)	2012-10-30
CL2009002183A1 (es)	2011-01-07
US20160303111A1 (en)	2016-10-20
AU2009335943A1 (en)	2013-10-24
US8236816B2 (en)	2012-08-07
IL255163B (en)	2019-01-31
TWI442923B (zh)	2014-07-01
US11318130B2 (en)	2022-05-03
SI2378876T1 (sl)	2019-05-31
US20110263635A1 (en)	2011-10-27
US20110257218A1 (en)	2011-10-20
US20110257216A1 (en)	2011-10-20
PT2378876T (pt)	2019-03-01
EP2378876A1 (en)	2011-10-26
PE20100469A1 (es)	2010-07-31
PA8855101A1 (es)	2010-07-27
US20200276182A1 (en)	2020-09-03
US20110263636A1 (en)	2011-10-27
US20110263634A1 (en)	2011-10-27
RS58566B1 (sr)	2019-05-31
TW201040173A (en)	2010-11-16
CO6400171A2 (es)	2012-03-15
EA201100984A1 (ru)	2012-01-30
US20110021555A1 (en)	2011-01-27
US8222270B2 (en)	2012-07-17
LT2378876T (lt)	2019-04-25
ES2720149T3 (es)	2019-07-18
US20110257217A1 (en)	2011-10-20
SMT201900195T1 (it)	2019-05-10
CR20110338A (es)	2011-11-10
MX346455B (es)	2017-03-21
US9370509B2 (en)	2016-06-21
EP2378876A4 (en)	2012-12-05
MX2011001555A (es)	2011-04-14

Publication	Publication Date	Title
BRPI0923164A2 (pt)	2016-01-26	formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica.
CY2020043I1 (el)	2021-03-12	Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
EA201101117A1 (ru)	2012-03-30	Ингибиторы дпп-4 для лечения диабета у детей
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BR112012017150A2 (pt)	2017-10-10	formulação de anticorpo e regimes terapêuticos.
CY2016053I1 (el)	2017-06-28	Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
CY1120741T1 (el)	2019-12-11	Θεραπεια οζωδους σκληρυνσης
BRPI1013698A2 (pt)	2016-04-26	métodos para tratamento com o uso de terapia de combinação
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2008001540A1 (es)	2009-05-22	Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001633A1 (es)	2008-12-12	Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2012003026A1 (es)	2013-02-01	Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
PL2468290T3 (pl)	2015-08-31	Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
BRPI0909818A2 (pt)	2015-10-06	métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
CL2013001591A1 (es)	2013-12-27	Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
BRPI0910780A2 (pt)	2016-08-09	uso de antagonistas de opióides para o tratamento da retenção urinária
BRPI0913377A2 (pt)	2015-11-24	regime de dosagem
BRPI0919231A2 (pt)	2018-01-09	agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
CL2013000881A1 (es)	2013-09-13	Combinaciones farmacéuticas que comprenden un componente (a) que corresponden a compuestos derivados de difenilurea omega-carboxiaril-sustituidos, (b) compuestos derivados de n-(2-arilamino)arilsulfonamida y (c) que son uno o más agentes farmaceuticos adicionales; y su uso en el tratamiento del cancer
CL2012002887A1 (es)	2013-01-18	Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
DK2310042T3 (da)	2013-03-04	Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
BRPI0912687A2 (pt)	2016-01-26	uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
DK1928427T3 (da)	2010-03-08	Hidtil ukendt dosisformulering
UY32735A (es)	2011-02-28	Formulaciones de imiquimod de concentración de dosificación inferior y regímenes de dosificación cortos para tratar verrugas genitales y perianales.
EA201390287A1 (ru)	2013-07-30	Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-05-15	B06I	Publication of requirement cancelled [chapter 6.9 patent gazette]
2018-06-05	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2018-10-23	B09B	Patent application refused [chapter 9.2 patent gazette]
2019-01-08	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL